APPLIED HEALTH OUTCOMES, INC.
NAPLES, FLORIDA

Dr. Paul C Langley is an internationally recognized health economist. Dr. Langley received his Ph.D. from Queens University Canada and over the past 30 years has held academic positions in health economics at the University of Arizona, University of Colorado and University of Minnesota. He has extensive pharmaceutical industry experience as was for 6 years, global head of health economics for 3M Pharmaceuticals. Dr. Langley is presently Director of Maimon Research LLC (www.maimonresearch.com) a boutique health consulting group based in Tucson. Dr. Langley has published extensively over the past 30 years with over 100 peer reviewed papers, reports and monographs on subjects ranging from the evidence base for precision and personalized medicine to multivariate analyses of the impact of pain on health status, quality of life, employment status and resource utilization.. He has undertaken projects in major health care markets to include The European Union, Canada, Australia, New Zealand as well as the US. Dr. Langley has particular focus and interest in the development of formulary submission guidelines that meet the required experimental and observational standards of normal science. As an adjunct professor, Dr. Langley is presently leading a research group in the College of Pharmacy, University of Minnesota to evaluate the evidence standards for claims presented to health care systems. A primary concern has been the submission to formulary committees of untestable claims for comparator pharmaceutical products and devices where the recipient has no ability to assess whether claims are right or if they are wrong. The research program is developing guidelines that require protocols to be submitted as part of a formulary package to enable claims to be evaluated and replicated in target patient populations, thus providing a credible evidence base for value propositions. Dr. Langley has published extensively in the areas of burden of illness and resource utilization to support therapy interventions. At the present time he is working with health care groups to facilitate the integration of claim data, laboratory data and electronic medical records to facilitate the targeting of patient populations. A number of research projects are underway to evaluate the merits of alternative management models for chronic and high cost event disease states. Working within an ACO framework, with a focus on older patients, a primary objective is to evaluate alternative physician practice based strategies to reduce the frequency of high cost events and assess the contributions of comorbidity clusters, adherence and persistence with medications. Dr. Paul C Langley is an internationally recognized health economist. Dr. Langley received his Ph.D. from Queens University Canada and over the past 30 years has held academic positions in health economics at the University of Arizona, University of Colorado and University of Minnesota. He has extensive pharmaceutical industry experience as was for 6 years, global head of health economics for 3M Pharmaceuticals. Dr. Langley is presently Director of Maimon Research LLC (www.maimonresearch.com) a boutique health consulting group based in Tucson. Dr. Langley has published extensively over the past 30 years with over 100 peer reviewed papers, reports and monographs on subjects ranging from the evidence base for precision and personalized medicine to multivariate analyses of the impact of pain on health status, quality of life, employment status and resource utilization.. He has undertaken projects in major health care markets to include The European Union, Canada, Australia, New Zealand as well as the US. Dr. Langley has particular focus and interest in the development of formulary submission guidelines that meet the required experimental and observational standards of normal science. As an adjunct professor, Dr. Langley is presently leading a research group in the College of Pharmacy, University of Minnesota to evaluate the evidence standards for claims presented to health care systems. A primary concern has been the submission to formulary committees of untestable claims for comparator pharmaceutical products and devices where the recipient has no ability to assess whether claims are right or if they are wrong. The research program is developing guidelines that require protocols to be submitted as part of a formulary package to enable claims to be evaluated and replicated in target patient populations, thus providing a credible evidence base for value propositions. Dr. Langley has published extensively in the areas of burden of illness and resource utilization to support therapy interventions. At the present time he is working with health care groups to facilitate the integration of claim data, laboratory data and electronic medical records to facilitate the targeting of patient populations. A number of research projects are underway to evaluate the merits of alternative management models for chronic and high cost event disease states. Working within an ACO framework, with a focus on older patients, a primary objective is to evaluate alternative physician practice based strategies to reduce the frequency of high cost events and assess the contributions of comorbidity clusters, adherence and persistence with medications. Dr. Paul C Langley is an internationally recognized health economist. Dr. Langley received his Ph.D. from Queens University Canada and over the past 30 years has held academic positions in health economics at the University of Arizona, University of Colorado and University of Minnesota. He has extensive pharmaceutical industry experience as was for 6 years, global head of health economics for 3M Pharmaceuticals. Dr. Langley is presently Director of Maimon Research LLC (www.maimonresearch.com) a boutique health consulting group based in Tucson. Dr. Langley has published extensively over the past 30 years with over 100 peer reviewed papers, reports and monographs on subjects ranging from the evidence base for precision and personalized medicine to multivariate analyses of the impact of pain on health status, quality of life, employment status and resource utilization.. He has undertaken projects in major health care markets to include The European Union, Canada, Australia, New Zealand as well as the US. Dr. Langley has particular focus and interest in the development of formulary submission guidelines that meet the required experimental and observational standards of normal science. As an adjunct professor, Dr. Langley is presently leading a research group in the College of Pharmacy, University of Minnesota to evaluate the evidence standards for claims presented to health care systems. A primary concern has been the submission to formulary committees of untestable claims for comparator pharmaceutical products and devices where the recipient has no ability to assess whether claims are right or if they are wrong. The research program is developing guidelines that require protocols to be submitted as part of a formulary package to enable claims to be evaluated and replicated in target patient populations, thus providing a credible evidence base for value propositions. Dr. Langley has published extensively in the areas of burden of illness and resource utilization to support therapy interventions. At the present time he is working with health care groups to facilitate the integration of claim data, laboratory data and electronic medical records to facilitate the targeting of patient populations. A number of research projects are underway to evaluate the merits of alternative management models for chronic and high cost event disease states. Working within an ACO framework, with a focus on older patients, a primary objective is to evaluate alternative physician practice based strategies to reduce the frequency of high cost events and assess the contributions of comorbidity clusters, adherence and persistence with medications.